CCMG
MYGN icon

Clark Capital Management Group’s Myriad Genetics MYGN Stock Holding History

Clark Capital Management Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,429
Closed -$1.23M – 318
2017
Q2 		$1.23M Buy
+47,429
New +$1.01M 0.05% 188
2013
Q4 		– Sell
-15,255
Closed -$358K – 364
2013
Q3 		$358K Buy
+15,255
New +$433K 0.03% 244

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Clark Capital Management Group's MYGN Position: Q3 2017 in Review

Clark Capital Management Group sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 47,429 shares — an estimated $1.23M sold.

Clark Capital Management Group first reported a position in MYGN in Q3 2013 and held it in 2 quarters. The position peaked at $1.23M in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • Clark Capital Management Group reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • Clark Capital Management Group sold 47,429 Myriad Genetics shares in Q3 2017, an estimated $1.23M.
  • Clark Capital Management Group first reported a position in Myriad Genetics in Q3 2013 and held it in 2 quarters.
  • Clark Capital Management Group's Myriad Genetics position peaked at $1.23M in Q2 2017.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Clark Capital Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.